Michigan is reporting record-high RSV vaccine coverage in infants under 1 at 35.7%. The state says there's been fewer RSV-related ER visits since the shots were introduced in 2023.
January 27, 2026 at 6:03 PM
Michigan is reporting record-high RSV vaccine coverage in infants under 1 at 35.7%. The state says there's been fewer RSV-related ER visits since the shots were introduced in 2023.
"A national hospital-based surveillance study from Australia found that the long-acting monoclonal antibody nirsevimab reduced respiratory syncytial virus (RSV)-related hospitalizations in infants under 12 months by over 80% during the country’s 2024 RSV season."
Analysis suggests nirsevimab cuts infant RSV hospitalizations 83%
Total RSV cases in children 12 months or younger were significantly lower in states with population-wide nirsevimab strategies.
www.cidrap.umn.edu
January 22, 2026 at 12:36 PM
"A national hospital-based surveillance study from Australia found that the long-acting monoclonal antibody nirsevimab reduced respiratory syncytial virus (RSV)-related hospitalizations in infants under 12 months by over 80% during the country’s 2024 RSV season."
In the phase 4 DAN-RSV trial, the RSV vaccine reduced the incidence of hospitalization for RSV-related respiratory tract disease as compared with no vaccine among adults 60 years of age or older. Full trial results and Research Summary: nej.md/4oT6ksQ
#MedSky #IDSky
#MedSky #IDSky
January 14, 2026 at 2:02 PM
In the phase 4 DAN-RSV trial, the RSV vaccine reduced the incidence of hospitalization for RSV-related respiratory tract disease as compared with no vaccine among adults 60 years of age or older. Full trial results and Research Summary: nej.md/4oT6ksQ
#MedSky #IDSky
#MedSky #IDSky
Primary outcome: RSV hospitalisations
Compared with historical seasons:
↓ 86% RSV-related LRTI hospitalisations in season 1
↓ 55% RSV-related LRTI hospitalisations in season 2
Compared with historical seasons:
↓ 86% RSV-related LRTI hospitalisations in season 1
↓ 55% RSV-related LRTI hospitalisations in season 2
January 14, 2026 at 1:23 PM
Primary outcome: RSV hospitalisations
Compared with historical seasons:
↓ 86% RSV-related LRTI hospitalisations in season 1
↓ 55% RSV-related LRTI hospitalisations in season 2
Compared with historical seasons:
↓ 86% RSV-related LRTI hospitalisations in season 1
↓ 55% RSV-related LRTI hospitalisations in season 2
with reduced hospitalizations for RSV-related lower respiratory tract infections & acute bronchiolitis in 2nd season.
However, the study also showed an increased risk of milder RSV-related outpatient visits in the second season, likely due to a shift in the timing of first RSV infection.
However, the study also showed an increased risk of milder RSV-related outpatient visits in the second season, likely due to a shift in the timing of first RSV infection.
January 14, 2026 at 1:01 AM
with reduced hospitalizations for RSV-related lower respiratory tract infections & acute bronchiolitis in 2nd season.
However, the study also showed an increased risk of milder RSV-related outpatient visits in the second season, likely due to a shift in the timing of first RSV infection.
However, the study also showed an increased risk of milder RSV-related outpatient visits in the second season, likely due to a shift in the timing of first RSV infection.
The NIRSE-GAL study looking at real world impact of nirsevimab in infants in Spain.
Of 12 492 eligible infants, 94·4% received immunization. RSV-related LRTI hospitalisations decreased by 85·9% in the 1st season and 55·3% in the 2nd.
www.thelancet.com/journals/lan... #IDSky
Of 12 492 eligible infants, 94·4% received immunization. RSV-related LRTI hospitalisations decreased by 85·9% in the 1st season and 55·3% in the 2nd.
www.thelancet.com/journals/lan... #IDSky
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective...
Universal infant nirsevimab prophylaxis markedly reduced RSV-related hospitalisations
and outpatient morbidity, with sustained reductions in RSV-related LRTI hospitalisations
into the second season an...
www.thelancet.com
January 13, 2026 at 2:07 PM
The NIRSE-GAL study looking at real world impact of nirsevimab in infants in Spain.
Of 12 492 eligible infants, 94·4% received immunization. RSV-related LRTI hospitalisations decreased by 85·9% in the 1st season and 55·3% in the 2nd.
www.thelancet.com/journals/lan... #IDSky
Of 12 492 eligible infants, 94·4% received immunization. RSV-related LRTI hospitalisations decreased by 85·9% in the 1st season and 55·3% in the 2nd.
www.thelancet.com/journals/lan... #IDSky
Among adults 60 years of age or older, the RSVpreF vaccine reduced the incidence of hospitalization for RSV-related respiratory tract disease as compared with no vaccine.
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults | NEJM
Respiratory syncytial virus (RSV) can cause serious illness in older adults. The bivalent
RSV prefusion F protein–based vaccine (RSVpreF) has been shown to prevent RSV-associated
respiratory illnes...
www.nejm.org
January 11, 2026 at 8:07 PM
Among adults 60 years of age or older, the RSVpreF vaccine reduced the incidence of hospitalization for RSV-related respiratory tract disease as compared with no vaccine.
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
DAN-RSV phase 4 trial: Respiratory syncytial virus causes some 470,000 hospitalizations and 33,000 deaths in industrialized countries annually. Research findings on the bivalent RSV prefusion F protein–based vaccine are summarized in a new Quick Take video. nej.md/4qKqmWE
#MedSky #CardioSky
#MedSky #CardioSky
January 11, 2026 at 8:01 PM
DAN-RSV phase 4 trial: Respiratory syncytial virus causes some 470,000 hospitalizations and 33,000 deaths in industrialized countries annually. Research findings on the bivalent RSV prefusion F protein–based vaccine are summarized in a new Quick Take video. nej.md/4qKqmWE
#MedSky #CardioSky
#MedSky #CardioSky
62% reduction in all-cause LRTI-related hospitalizations in infants and young children who received RSV vaccine (nirsevimab) compared with controls…
…RFK Jr has now stopped 81% of new infant RSV vaccinations
www.theguardian.com/us-news/2026...
…RFK Jr has now stopped 81% of new infant RSV vaccinations
www.theguardian.com/us-news/2026...
Evidence shows benefit of RSV vaccines as Trump officials push restrictions
Shots to prevent respiratory syncytial virus recommended only for high-risk babies even as experts hail jabs’ success
www.theguardian.com
January 11, 2026 at 4:54 PM
62% reduction in all-cause LRTI-related hospitalizations in infants and young children who received RSV vaccine (nirsevimab) compared with controls…
…RFK Jr has now stopped 81% of new infant RSV vaccinations
www.theguardian.com/us-news/2026...
…RFK Jr has now stopped 81% of new infant RSV vaccinations
www.theguardian.com/us-news/2026...
USA: Respiratory virus activity in the US is high, driven by influenza and RSV. COVID remains relatively low but is rising.
Flu positivity is 24.7%, with 8 recent child deaths linked to influenza A (H3N2).
RSV-related ED visits and hospitalisations in children aged 0–4 are increasing.
Flu positivity is 24.7%, with 8 recent child deaths linked to influenza A (H3N2).
RSV-related ED visits and hospitalisations in children aged 0–4 are increasing.
US respiratory virus activity reaches high levels as flu, RSV spread
www.cidrap.umn.edu
January 10, 2026 at 4:21 AM
USA: Respiratory virus activity in the US is high, driven by influenza and RSV. COVID remains relatively low but is rising.
Flu positivity is 24.7%, with 8 recent child deaths linked to influenza A (H3N2).
RSV-related ED visits and hospitalisations in children aged 0–4 are increasing.
Flu positivity is 24.7%, with 8 recent child deaths linked to influenza A (H3N2).
RSV-related ED visits and hospitalisations in children aged 0–4 are increasing.
Among adults 60 years of age or older, the RSVpreF vaccine reduced the incidence of hospitalization for RSV-related respiratory tract disease @nejm.org
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
January 9, 2026 at 2:35 AM
Among adults 60 years of age or older, the RSVpreF vaccine reduced the incidence of hospitalization for RSV-related respiratory tract disease @nejm.org
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Infants who received nirsevimab after birth experienced lower rates of RSV-related hospitalization and severe complications compared to those protected by maternal vaccination during pregnancy. doi.org/hbhbs2
Infants receiving nirsevimab fare better against RSV compared to those with maternal vaccination
Respiratory syncytial virus (RSV) is a common virus that affects the nose, throat, and lungs. For most healthy adults and children, it causes only mild, cold-like symptoms and goes away on its own.
medicalxpress.com
January 6, 2026 at 2:50 PM
Infants who received nirsevimab after birth experienced lower rates of RSV-related hospitalization and severe complications compared to those protected by maternal vaccination during pregnancy. doi.org/hbhbs2
And in other news related to our general health and well-being: HHS to narrow recommendations for vaccination against RSV, meningococcal disease, hepatitis B, and hepatitis A to children at higher risk for infections, and make it tougher to get vaccinations against flu, Covid-19 and rotavirus.
HHS will overhaul childhood vaccine schedule to recommend fewer shots | CNN
The US Department of Health and Human Services will recommend fewer vaccines for most American children, health officials said Monday.
www.cnn.com
January 5, 2026 at 7:16 PM
And in other news related to our general health and well-being: HHS to narrow recommendations for vaccination against RSV, meningococcal disease, hepatitis B, and hepatitis A to children at higher risk for infections, and make it tougher to get vaccinations against flu, Covid-19 and rotavirus.
Flu and related viruses such as RSV are on the rise across the country as Ohio has recorded the first flu related death of the season
https://yourradioplace.com/number-of-flu-cases-rising-rapidly-across-the-u-s-driven-in-part-by-a-new-variant/
https://yourradioplace.com/number-of-flu-cases-rising-rapidly-across-the-u-s-driven-in-part-by-a-new-variant/
January 5, 2026 at 2:46 PM
Flu and related viruses such as RSV are on the rise across the country as Ohio has recorded the first flu related death of the season
https://yourradioplace.com/number-of-flu-cases-rising-rapidly-across-the-u-s-driven-in-part-by-a-new-variant/
https://yourradioplace.com/number-of-flu-cases-rising-rapidly-across-the-u-s-driven-in-part-by-a-new-variant/
January 2, 2026 at 11:36 AM
Hi I’m
Cystic Fibrosis
Cystic Fibrosis Related Diabetes
Kidney Damage
Spitolactone
COVID
RSV
Influenza
Alcohol
Cystic Fibrosis
Cystic Fibrosis Related Diabetes
Kidney Damage
Spitolactone
COVID
RSV
Influenza
Alcohol
January 2, 2026 at 5:36 AM
Hi I’m
Cystic Fibrosis
Cystic Fibrosis Related Diabetes
Kidney Damage
Spitolactone
COVID
RSV
Influenza
Alcohol
Cystic Fibrosis
Cystic Fibrosis Related Diabetes
Kidney Damage
Spitolactone
COVID
RSV
Influenza
Alcohol
Nirsevimab outperforms RSVpreF vaccine in reducing hospitalizations and severe outcomes for infants with RSV-related infections.
by Jabagi MJ, Bertrand M (...) Zureik M et 3 al. in JAMA #MedSky
👉 get more here
📖 read the article: https://jamanetwork.com/journals/jama/article-abstract/2843212
by Jabagi MJ, Bertrand M (...) Zureik M et 3 al. in JAMA #MedSky
👉 get more here
📖 read the article: https://jamanetwork.com/journals/jama/article-abstract/2843212
December 31, 2025 at 8:34 PM
Nirsevimab outperforms RSVpreF vaccine in reducing hospitalizations and severe outcomes for infants with RSV-related infections.
by Jabagi MJ, Bertrand M (...) Zureik M et 3 al. in JAMA #MedSky
👉 get more here
📖 read the article: https://jamanetwork.com/journals/jama/article-abstract/2843212
by Jabagi MJ, Bertrand M (...) Zureik M et 3 al. in JAMA #MedSky
👉 get more here
📖 read the article: https://jamanetwork.com/journals/jama/article-abstract/2843212
Nirsevimab, som ikke er en vaccine, men et monoklonalt antistof..."provides real-world protective benefits beyond those demonstrated or recognized for RSV-specific outcomes, further supporting its implementation in infant immunization programs to reduce the respiratory-related disease burden.."
Nirsevimab may help prevent severe respiratory illnesses beyond RSV in infants, young kids
www.cidrap.umn.edu
December 30, 2025 at 9:53 AM
Nirsevimab, som ikke er en vaccine, men et monoklonalt antistof..."provides real-world protective benefits beyond those demonstrated or recognized for RSV-specific outcomes, further supporting its implementation in infant immunization programs to reduce the respiratory-related disease burden.."
Nirsevimab may help prevent severe respiratory illnesses beyond RSV in infants, young kids
https://www.newsbeep.com/au/379152/
In addition to reducing respiratory syncytial virus (RSV)–related hospitalizations and emergency department (ED) visits, nirsevimab (Beyfortus) may also…
https://www.newsbeep.com/au/379152/
In addition to reducing respiratory syncytial virus (RSV)–related hospitalizations and emergency department (ED) visits, nirsevimab (Beyfortus) may also…
Nirsevimab may help prevent severe respiratory illnesses beyond RSV in infants, young kids - Australia News Beep
In addition to reducing respiratory syncytial virus (RSV)–related hospitalizations and emergency department (ED) visits, nirsevimab (Beyfortus) may also
www.newsbeep.com
December 29, 2025 at 11:20 PM
Nirsevimab may help prevent severe respiratory illnesses beyond RSV in infants, young kids
https://www.newsbeep.com/au/379152/
In addition to reducing respiratory syncytial virus (RSV)–related hospitalizations and emergency department (ED) visits, nirsevimab (Beyfortus) may also…
https://www.newsbeep.com/au/379152/
In addition to reducing respiratory syncytial virus (RSV)–related hospitalizations and emergency department (ED) visits, nirsevimab (Beyfortus) may also…
Nirsevimab may help prevent severe respiratory illnesses beyond RSV in infants, young kids
https://www.newsbeep.com/ca/375993/
In addition to reducing respiratory syncytial virus (RSV)–related hospitalizations and emergency department (ED) visits, nirsevimab (Beyfortus) may also…
https://www.newsbeep.com/ca/375993/
In addition to reducing respiratory syncytial virus (RSV)–related hospitalizations and emergency department (ED) visits, nirsevimab (Beyfortus) may also…
Nirsevimab may help prevent severe respiratory illnesses beyond RSV in infants, young kids - Canada News Beep
In addition to reducing respiratory syncytial virus (RSV)–related hospitalizations and emergency department (ED) visits, nirsevimab (Beyfortus) may also
www.newsbeep.com
December 29, 2025 at 10:40 PM
Nirsevimab may help prevent severe respiratory illnesses beyond RSV in infants, young kids
https://www.newsbeep.com/ca/375993/
In addition to reducing respiratory syncytial virus (RSV)–related hospitalizations and emergency department (ED) visits, nirsevimab (Beyfortus) may also…
https://www.newsbeep.com/ca/375993/
In addition to reducing respiratory syncytial virus (RSV)–related hospitalizations and emergency department (ED) visits, nirsevimab (Beyfortus) may also…
This is almost like when I got RSV for Christmas last year. Which resulted in a turkey related crime at home which thankfully was not repeated this year. It’s not as bad as RSV was, but still annoying.
December 28, 2025 at 9:51 PM
This is almost like when I got RSV for Christmas last year. Which resulted in a turkey related crime at home which thankfully was not repeated this year. It’s not as bad as RSV was, but still annoying.
Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus–Related Hospitalization in Newborns
In this French nationwide study, infant immunization with nirsevimab was associated with a lower risk of RSV-related hospitalization compared with maternal vaccination with the RSVpreF vaccine
In this French nationwide study, infant immunization with nirsevimab was associated with a lower risk of RSV-related hospitalization compared with maternal vaccination with the RSVpreF vaccine
Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus–Related Hospitalization in Newborns
This population-based study used data from the French National Health Data System to compare risk associations for respiratory syncytial virus (RSV)–related infant hospitalization and other outcomes a...
jamanetwork.com
December 28, 2025 at 3:21 AM
Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus–Related Hospitalization in Newborns
In this French nationwide study, infant immunization with nirsevimab was associated with a lower risk of RSV-related hospitalization compared with maternal vaccination with the RSVpreF vaccine
In this French nationwide study, infant immunization with nirsevimab was associated with a lower risk of RSV-related hospitalization compared with maternal vaccination with the RSVpreF vaccine
Newborn #nirsevimab immunization was associated with lower risks of RSV-related hospitalization and severe outcomes compared to maternal #RSVpreF vaccination.
ja.ma/4pg9vtw
ja.ma/4pg9vtw
December 26, 2025 at 8:15 PM
Newborn #nirsevimab immunization was associated with lower risks of RSV-related hospitalization and severe outcomes compared to maternal #RSVpreF vaccination.
ja.ma/4pg9vtw
ja.ma/4pg9vtw